#1
|
|||
|
|||
ÝÝÄ
Õîòåëîñü áû óñëûøàòü ìíåíèÿ ïî ïîâîäó ëå÷åíèÿ ÝÝÄ, îñíîâàííûå íà ëè÷íîì îïûòå.
|
#2
|
|||
|
|||
Ëå÷åíèå êåðàòîïàòèé âåñüìà íåáëàãîäàðíàÿ çàäà÷à. Íî, òåì íå ìåíåå, ïðèõîäèòñÿ ïåðèîäè÷åñêè ýòèì çàíèìàòüñÿ. Îñíîâíûì ïîñòàâùèêîì ýòîãî ñîñòîÿíèÿ ÿâëÿþòñÿ îïåðàöèè ïî ïîâîäó êàòàðàêòû.
Ëå÷åíèå íà÷èíàåòñÿ ïðè âîçíèêíîâåíèè îòåêà â ïîñëåîïåðàöèîííîì ïåðèîäå. Íàçíà÷àþòñÿ ãèïîòåíçèâíûå ïðåïàðàòû, äàæå åñëè ÂÃÄ íîðìàëüíîå. Ïîä êîíúþíêòèâó àñêîðáèíîâàÿ êèñëîòà 0,5 ìë ¹ 5 èëè ãèñòîõðîì ¹5-7 Îðîøåíèÿ ðîãîâèöû 20-40% ãëþêîçîé 6 ðàç â äåíü. Ãåìîäåç + ðåòàáîëèë (5:1) 6 ðàç â äåíü. Ñòèìóëÿöèè ãåëèé-íåîíîâûì ëàçåðîì. Ïðåïàðàòû âûáîðà Êîðíåðåãåëü, âèòàñèê è ò.ï.  ïîñëåäóþùåì, åñëè ïðîöåññ íå êóïèðóåòñÿ ëå÷åíèå ïðîäîëæàåòñÿ ñ èñïîëüçîâàíèåì èíäèâèäóàëüíîé êîìáèíàöèè ïðåïàðàòîâ. |
#3
|
|||
|
|||
À êàê íàñ÷åò àëüôà-òîêîôåðîëà (âèò. Å) 10%, 30% ìàñë. ð-ð â èíñòèëÿöèÿõ?
|
#4
|
|||
|
|||
|
#5
|
|||
|
|||
Ïðè ðàçâèòèè ÝÝÄ ìû ïðèìåíÿåì ñõåìó, ïðåäëîæåííóþ Âàìè, êðîìå ãåìîäåçà è ðåòàáîëèëà. Èíîãäà - ðèáîôëàâèí è âèò. Å â êà÷åñòâå àíòèîêñèäàíòà è â êàêîé-òî ñòåïåíè â êà÷åñòâå îñìîëÿðíîãî ðàñòâîðà. Êàêîãî-òî âûðàæåííîãî ýôôåêòà ïðè ÝÝÄ ìû íå âèäåëè. Äîâîëüíî íåïëîõî Âèò Å ïðè òðàíçèòîðíûõ îòåêàõ ðîãîâèöû ñ äåñöåìåòèòîì ïîñëå ÝÝÊ (ôàêî, ÌÔÔ) â ðàííåì ïîñëåîïåðàöèîííîì ïåðèîäå. Ïîñëå ãëþêîçû 40% çàêàïûâàåì òîêîôåðîë 10%, õîðîøî îáâîëàêèâàåò, ñîçäàåò ìàñëÿíóþ ïëåíêó è áîëüíûå íå îùóùàþò ðåçè è ñóõîñòè ïîñëå ãëþêîçû. Êîíå÷íî, âñå ýòî íà óðîâíå ñóáúåêòèâíûõ îùóùåíèé, íî âñå æå... À êàê Âû îòíîñèòåñü ê Áàëàðïàíó?
|
#6
|
|||
|
|||
|
#7
|
|||
|
|||
Ãëåêîìåí äàâíî íå âèäåë, íî ìû èñïîëüçóåì ãåïàðèí â ñóáêîíúþíêòèâàëüíûõ èíúåêöèÿõ.
|
#8
|
|||
|
|||
Óâàæàåìûé äîêòîð Êðàíö! Ïðîñüáà ðàññêàçàòü êàê ðåøàþòñÿ ïîäîáíûå ïðîáëåìû â Èçðàèëå.
|
#9
|
|||
|
|||
Æàëü, ÷òî íå äîæäàëèñü îòâåòà îò äîêòîðà Êðàíöà. Íî íàáðåë íà àìåðèêàíñêèé ïðîòîêîë ëå÷åíèÿ áóëëåçíîé êåðàòîïàòèè.
Âîò îáîáùåííî ðàçäåë ìåäèêàìåíòîçíîé òåðàïèè. Ïðèìåíÿþòñÿ ãèïåðòîíè÷åñêèå âåùåñòâà.  ÷àñòíîñòè 2-5% ðàñòâîð èëè ìàçü íàòðèÿ õëîðèäà, îñîáåííî â óòðåííèå ÷àñû 4-5 ðàç êàæäûé ÷àñ. Íàðÿäó ñ ýòèì ïðè íåîáõîäèìîñòè ïðîâîäèòñÿ ëå÷åíèå âîñïàëèòåëüíîãî ïðîöåññà è ñíèæåíèå ÂÃÄ ïðè åãî ïîâûøåíèè. Íîøåíèå ìÿãêèõ êîíòàêòíûõ ëèíç 1-2 íåäåëè äëÿ êóïèðîâàíèå áîëåâîãî ñèíäðîìà è äèñêîìôîðòà íàðÿäó ñ çàêàïûâàíèåì àíòèáèîòèêîâ (àìèíîãëèêîçèäîâ) 2-4 ðàçà â äåíü äëÿ ïðîôèëàêòèêè èíôåêöèè. Ó ïàöèåíòîâ ñ íèçêèì çðåíèåì è âûðàæåííûì áîëåâûì ñèíäðîìîì ìîæåò ïðèìåíÿòüñÿ ïðîêîë îáëàñòè áóëë èãëîé 25 ãåéò äî Áîóìåíîâîé ìåìáðàíû èëè íåñêîëüêî íèæå. Ýòî ÷àñòî ïðèâîäèò ê èñ÷åçíîâåíèþ áóëë. Ïîäîáíîãî ýôôåêòà äîáèâàþòñÿ è ñ ïîìîùüþ ýêñèìåðëàçåðíîé ôîòîêåðàòýêòîìèè. |
#10
|
|||
|
|||
Èç ìåäñêåéï
Orphan Drug Autologous Cultured Endothelial Cells on a Donor Human Corneal Disk for Corneal Disorders On June 1, the FDA granted orphan drug designation to autologous cultured endothelial cells on a donor human corneal disk (Cellular Bioengineering, Inc) for the treatment of Fuch's dystrophy, bullous keratopathy, and pseudophakic bullous keratopathy. |
#11
|
|||
|
|||
Amniotic Membrane Transplantation for Symptomatic Bullous Keratopathy
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] A comparison of different depth ablations in the treatment of painful bullous keratopathy with phototherapeutic keratectomy [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#12
|
|||
|
|||
Annular keratotomy for the treatment of painful bullous keratopathy
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |